Demographics, baseline characteristics and disease status
| Enrolled set n=1415 | Follow-up set n=861 | |
| Age (years), mean±SD | 69.8±11.6 | 72.4±10.8 |
| Male | 979 (69.2) | 583 (67.7) |
| BMI (kg/m2), mean±SD | 29.3±5.6 | 28.7±5.3 |
| NYHA functional class, n (%) | ||
| I | 224 (15.9) | 85 (9.9) |
| II | 700 (49.8) | 422 (49.1) |
| III | 458 (32.6) | 333 (38.7) |
| IV | 25 (1.8) | 20 (2.3) |
| LVEF (%) in PCP chart, mean±SD | 35±9 | 33±8 |
| Primary aetiology, n (%) | ||
| Ischaemic | 860 (60.9) | 541 (62.8) |
| Hypertension | 166 (30.1) | 105 (32.9) |
| Cardiac arrhythmia | 106 (19.2) | 72 (22.6) |
| Valvular disease | 68 (12.3) | 41 (12.9) |
| Duration of HF (years), mean±SD | 6.2±5.9 | 6.4±6 |
| Heart rate (bpm), mean±SD (n) | 71±11 (1411) | 72±10 (749) |
| Systolic blood pressure (mm Hg), mean±SD (n) | 128.1±16.9 (1415) | 124.8±15.7 (750) |
| <100 mm Hg, % (n/N) | 2.9 (41/1415) | 3.3 (28/861) |
| Diastolic blood pressure (mm Hg), mean±SD (n) | 75.9±10.7 (1415) | 74.5±9.9 (750) |
| Plasma potassium*, % (n/N) | ||
| ≤5.5 mmol/L | 95.9 (1172/1222) | 92.0 (219/238) |
| >5.5 mmol/L | 4.1 (50/1222) | 8.0 (19/238) |
| GFR* according to MDRD formula (mL/min), mean±SD (n) | 66.5±29.6 (774) | 57.6±28.8 (245)† |
| <30 mL/min/m2, % (n/N) | 4.2 (54/1285) | 12.2 (30/245) |
| ≥30 mL/min/m2, % (n/N) | 95.8 (1231/1285) | 87.8 (215/245) |
| NT-pro-BNP (pg/mL), median (IQR) | 930 (59–10317) | 1708 (601–9001) |
| NT-pro-BNP, n (%) | ||
| <600 pg/mL | 495 (35.0) | 0 (0.0) |
| ≥600 pg/mL to <2000 pg/mL | 455 (32.2) | 430 (49.9) |
| ≥2000 pg/mL | 465 (32.9) | 431 (50.1) |
*Assessment of the value was done by the PCP in their local laboratory.
†Postreferral visit (follow-up set).
BMI, body mass index; GFR, glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MDRD, modification of diet in renal disease; NT-pro-BNP, N-terminal-pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCP, primary care physician.;